Načítá se...
TARGETED THERAPIES: Afatinib—new therapy option for EGFR-mutant lung cancer
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of pati...
Uloženo v:
| Vydáno v: | Nat Rev Clin Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665630/ https://ncbi.nlm.nih.gov/pubmed/23959269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.154 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|